Would you consider just treating radiographic residual disease (as opposed to all original sites of disease involvement, per ILROG guidelines) in a patient with bulky early-stage Hodgkin's lymphoma of the mediastinum?

Topics: Hematologic Malignancies • Radiation Oncology • Hematology

For example, in a young patient where standard fields would be very large and you want to minimize toxicity

Answer from: Radiation Oncologist at Academic Institution

If the patient is treated with > 4 cycles of chemotherapy and the disease is considered chemo-refractory, and if dose constraints to critical structures especially to the lungs can be achieved, I would recommend treating all the original sites of disease involvement, then add boost to the residua...

Comments

Medical Oncologist at Cancer Care Specialists/Renown Oncology/UNR
Is XRT needed in bulky disease after PET negative ...

Related Questions